Engineered immune cells target aggressive brain tumors in new trial
NCT ID NCT07544992
First seen Apr 30, 2026 · Last updated May 09, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment for people with high-grade gliomas that have returned or worsened. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into the brain. The main goals are to check safety and find the best dose in 24 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.